Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya - 2NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says
- 3Monetary Security: Building Serious areas of strength for an Establishment
- 4A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- 5Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- Style Narratives: A Survey of \Patterns and Styles Assessed\ Design
- Worldwide Objections Ideal For A Golf Outing
- Lilly, Novo lock horns in India's obesity drug race
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- A Time of Careful Eating: Individual Tests in Nourishment
- Great DSLR Cameras for Photography Devotees
- Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- 4 astronauts are en route home from ISS after medical issue forces early exit
- Volkswagen in talks with defence firms on use of Germany plant: CEO
